Vertex Provides an Update on the VX-880 Clinical Trial
Vertex provides an update on their Phase 1/2 Clinical Trial for VX-880, including data from three participants and details around the clinical hold.
The First Gene-Edited Cell Replacement Therapy Takes a Step Forward
The first person has received ViaCyte and CRISPR's cell replacement therapy.
Stem Cell Replacement Therapy: Its Time has Begun
ViaCyte has results on its second stem cell-based technology, providing evidence of stem cells secreting insulin in response to meal consumption.
Progress Toward Cures: Thoughts at Year’s End from Breakthrough T1D’s CEO
Breakthrough T1D CEO Aaron Kowalski, Ph.D., weighs in on the exciting news surrounding stem cell-derived beta cell replacement therapies, now in human clinical trials.
First-in-Human Gene-Edited Stem Cell Trial? Check.
ViaCyte, a beta cell replacement company long supported by Breakthrough T1D, and CRISPR Therapeutics have a new first: Gene-editing for type 1 diabetes.
Vertex Shares Data from Their Stem Cell-Derived Therapy—and It’s Outstanding
In February, Vertex announced they were beginning a clinical trial for VX-880, their stem cell-derived therapy for use in people with type 1 diabetes (T1D). Today, they announced that the first person to receive this therapy now needs 91% less insulin 90 days after receiving an infusion of these fully differentiated cells at just half […]
Vertex Pharmaceuticals Investigating Cell Therapy for Type 1 Diabetes
Vertex is currently enrolling for a clinical trial evaluating their stem cell derived islet cell infusion therapy, VX-880.
Breakthrough T1D & NIH Workshop at the Intersection of Immunology and Bioengineering
Breakthrough T1D and NIH bring together top scientists and engineers to strategize on how to allow implanted beta cells to thrive.
Video: ADA’s Scientific Sessions: Day 4
Here is Dr. Camillo Ricordi to share his key takeaways from day 4 from the American Diabetes Association's Scientific Sessions.
(Beta Cell) Stressing You Out?
You thought that beta cells were passive participants in their own immune-mediated death, leading to type 1 diabetes (T1D)? Wrong.
